A citation-based method for searching scientific literature

Daniel Y Wang, Joe-Elie Salem, Justine V Cohen, Sunandana Chandra, Christian Menzer, Fei Ye, Shilin Zhao, Satya Das, Kathryn E Beckermann, Lisa Ha, W Kimryn Rathmell, Kristin K Ancell, Justin M Balko, Caitlin Bowman, Elizabeth J Davis, David D Chism, Leora Horn, Georgina V Long, Matteo S Carlino, Benedicte Lebrun-Vignes, Zeynep Eroglu, Jessica C Hassel, Alexander M Menzies, Jeffrey A Sosman, Ryan J Sullivan, Javid J Moslehi, Douglas B Johnson. JAMA Oncol 2018
Times Cited: 648







List of co-cited articles
646 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
Michael A Postow, Robert Sidlow, Matthew D Hellmann. N Engl J Med 2018
42

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, Michael B Atkins, Kelly J Brassil, Jeffrey M Caterino, Ian Chau, Marc S Ernstoff, Jennifer M Gardner, Pamela Ginex,[...]. J Clin Oncol 2018
38

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
I Puzanov, A Diab, K Abdallah, C O Bingham, C Brogdon, R Dadu, L Hamad, S Kim, M E Lacouture, N R LeBoeuf,[...]. J Immunother Cancer 2017
749
27

Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
Douglas B Johnson, Justin M Balko, Margaret L Compton, Spyridon Chalkias, Joshua Gorham, Yaomin Xu, Mellissa Hicks, Igor Puzanov, Matthew R Alexander, Tyler L Bloomer,[...]. N Engl J Med 2016
917
24

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
Joe-Elie Salem, Ali Manouchehri, Melissa Moey, Bénédicte Lebrun-Vignes, Lisa Bastarache, Antoine Pariente, Aurélien Gobert, Jean-Philippe Spano, Justin M Balko, Marc P Bonaca,[...]. Lancet Oncol 2018
296
21

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J B A G Haanen, F Carbonnel, C Robert, K M Kerr, S Peters, J Larkin, K Jordan. Ann Oncol 2017
814
20

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
Syed S Mahmood, Michael G Fradley, Justine V Cohen, Anju Nohria, Kerry L Reynolds, Lucie M Heinzerling, Ryan J Sullivan, Rongras Damrongwatanasuk, Carol L Chen, Dipti Gupta,[...]. J Am Coll Cardiol 2018
468
18

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
17

Cancer immunotherapy using checkpoint blockade.
Antoni Ribas, Jedd D Wolchok. Science 2018
16

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Filipe Martins, Latifyan Sofiya, Gerasimos P Sykiotis, Faiza Lamine, Michel Maillard, Montserrat Fraga, Keyvan Shabafrouz, Camillo Ribi, Anne Cairoli, Yan Guex-Crosier,[...]. Nat Rev Clin Oncol 2019
368
15

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
15

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
Jarushka Naidoo, Xuan Wang, Kaitlin M Woo, Tunc Iyriboz, Darragh Halpenny, Jane Cunningham, Jamie E Chaft, Neil H Segal, Margaret K Callahan, Alexander M Lesokhin,[...]. J Clin Oncol 2017
466
14

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.
Javid J Moslehi, Joe-Elie Salem, Jeffrey A Sosman, Bénédicte Lebrun-Vignes, Douglas B Johnson. Lancet 2018
332
14

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
Jeffrey S Weber, F Stephen Hodi, Jedd D Wolchok, Suzanne L Topalian, Dirk Schadendorf, James Larkin, Mario Sznol, Georgina V Long, Hewei Li, Ian M Waxman,[...]. J Clin Oncol 2017
547
12

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
12

Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.
Joe-Elie Salem, Yves Allenbach, Aurore Vozy, Nicolas Brechot, Douglas B Johnson, Javid J Moslehi, Mathieu Kerneis. N Engl J Med 2019
136
12

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
11

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki H Lee, Maike de Wit,[...]. N Engl J Med 2017
11

Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.
Marion Escudier, Jennifer Cautela, Nausicaa Malissen, Yann Ancedy, Morgane Orabona, Johan Pinto, Sandrine Monestier, Jean-Jacques Grob, Ugo Scemama, Alexis Jacquier,[...]. Circulation 2017
194
11

Immune Checkpoint Inhibitor Toxicity in 2018.
Douglas B Johnson, Sunandana Chandra, Jeffrey A Sosman. JAMA 2018
111
11

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
A M Menzies, D B Johnson, S Ramanujam, V G Atkinson, A N M Wong, J J Park, J L McQuade, A N Shoushtari, K K Tsai, Z Eroglu,[...]. Ann Oncol 2017
415
10

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
10

Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology
Marc P Bonaca, Benjamin A Olenchock, Joe-Elie Salem, Stephen D Wiviott, Stephane Ederhy, Ariel Cohen, Garrick C Stewart, Toni K Choueiri, Marcelo Di Carli, Yves Allenbach,[...]. Circulation 2019
111
10


Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.
Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba, Keita Kudo, Kimio Yonesaka, Ryoji Kato, Hiroyasu Kaneda, Yoshikazu Hasegawa, Kaoru Tanaka, Masayuki Takeda,[...]. JAMA Oncol 2018
420
10

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
9

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean-Jacques Grob, C Lance Cowey, Christopher D Lao, John Wagstaff, Dirk Schadendorf, Pier F Ferrucci,[...]. N Engl J Med 2017
9

Cardiovascular toxicities associated with immune checkpoint inhibitors.
Jiun-Ruey Hu, Roberta Florido, Evan J Lipson, Jarushka Naidoo, Reza Ardehali, Carlo G Tocchetti, Alexander R Lyon, Robert F Padera, Douglas B Johnson, Javid Moslehi. Cardiovasc Res 2019
126
9

Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.
Lili Zhang, Magid Awadalla, Syed S Mahmood, Anju Nohria, Malek Z O Hassan, Franck Thuny, Daniel A Zlotoff, Sean P Murphy, James R Stone, Doll Lauren Alexandra Golden,[...]. Eur Heart J 2020
78
11

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
8

Management of Immunotherapy-Related Toxicities, Version 1.2019.
John A Thompson, Bryan J Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E Budde, Luciano Costa, Marianne Davies, David Dunnington,[...]. J Natl Compr Canc Netw 2019
184
8

Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
Mizuki Nishino, Anita Giobbie-Hurder, Hiroto Hatabu, Nikhil H Ramaiya, F Stephen Hodi. JAMA Oncol 2016
323
8

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
H Nishimura, T Okazaki, Y Tanaka, K Nakatani, M Hara, A Matsumori, S Sasayama, A Mizoguchi, H Hiai, N Minato,[...]. Science 2001
8

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.
P Waterhouse, J M Penninger, E Timms, A Wakeham, A Shahinian, K P Lee, C B Thompson, H Griesser, T W Mak. Science 1995
8

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
Morganna Freeman-Keller, Youngchul Kim, Heather Cronin, Allison Richards, Geoffrey Gibney, Jeffrey S Weber. Clin Cancer Res 2016
444
8


PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.
Mizuki Nishino, Nikhil H Ramaiya, Mark M Awad, Lynette M Sholl, Jennifer A Maattala, Myriam Taibi, Hiroto Hatabu, Patrick A Ott, Philippe F Armand, F Stephen Hodi. Clin Cancer Res 2016
233
7

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.
Krista Dubin, Margaret K Callahan, Boyu Ren, Raya Khanin, Agnes Viale, Lilan Ling, Daniel No, Asia Gobourne, Eric Littmann, Curtis Huttenhower,[...]. Nat Commun 2016
415
7

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S Carlino,[...]. N Engl J Med 2018
739
7

Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, Georgina V Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. N Engl J Med 2015
7

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
S Champiat, O Lambotte, E Barreau, R Belkhir, A Berdelou, F Carbonnel, C Cauquil, P Chanson, M Collins, A Durrbach,[...]. Ann Oncol 2016
455
7

Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Yukihiro Toi, Shunichi Sugawara, Jun Sugisaka, Hirotaka Ono, Yosuke Kawashima, Tomoiki Aiba, Sachiko Kawana, Ryohei Saito, Mari Aso, Kyoji Tsurumi,[...]. JAMA Oncol 2019
81
8

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
Lucie Heinzerling, Patrick A Ott, F Stephen Hodi, Aliya N Husain, Azadeh Tajmir-Riahi, Hussein Tawbi, Matthias Pauschinger, Thomas F Gajewski, Evan J Lipson, Jason J Luke. J Immunother Cancer 2016
269
7

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
7

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, Helen J Gogas, Ana M Arance, C Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion-Sileni, Ivan Marquez-Rodas,[...]. N Engl J Med 2017
975
7

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
Kathryn C Arbour, Laura Mezquita, Niamh Long, Hira Rizvi, Edouard Auclin, Andy Ni, Gala Martínez-Bernal, Roberto Ferrara, W Victoria Lai, Lizza E L Hendriks,[...]. J Clin Oncol 2018
389
7

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
7

Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution.
Céline Anquetil, Joe-Elie Salem, Bénédicte Lebrun-Vignes, Douglas B Johnson, Andrew L Mammen, Werner Stenzel, Sarah Léonard-Louis, Olivier Benveniste, Javid J Moslehi, Yves Allenbach. Circulation 2018
74
9

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Monica Khunger, Sagar Rakshit, Vinay Pasupuleti, Adrian V Hernandez, Peter Mazzone, James Stevenson, Nathan A Pennell, Vamsidhar Velcheti. Chest 2017
199
7

Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
J M Michot, C Bigenwald, S Champiat, M Collins, F Carbonnel, S Postel-Vinay, A Berdelou, A Varga, R Bahleda, A Hollebecque,[...]. Eur J Cancer 2016
998
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.